Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma". Cleveland BioLabs Inc. had been founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. It had license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute, and specialized in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod. Genome Protection Inc. subsequently received a $10.5 million (US) investment from Russian oligarch Roman Abramovich. More information...
According to PR-model, cbiolabs.com is ranked 2,538,057th in multilingual Wikipedia, in particular this website is ranked 316,612th in Russian Wikipedia.
The website is placed before festaunita.it and after ourmissionispossible.org in the BestRef global ranking of the most important sources of Wikipedia.
